Boule Diagnostics

5.40 SEK

-8.78 %

Less than 1K followers

BOUL

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-8.78 %

-15.63 %

-11.48 %

-33.33 %

-39.87 %

-38.36 %

-58.14 %

-85.16 %

-41.34 %

Boule Diagnostics operates in the medical technology industry and focuses on the development and manufacture of diagnostic instruments for hematology. The company's products are aimed at healthcare institutions and laboratories. The business is global with a main presence in Europe, North America and Asia. Boule Diagnostics was founded in 1956 and is headquartered in Spånga, Sweden.

Market cap

209.7M SEK

Turnover

430.39K SEK

Revenue

558.5M

EBIT %

-46.09 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

11.2

2026

Annual report '25

28.4

2026

Interim report Q1'26

13.5

2026

General meeting '26

All

Press releases

3rd party

ShowingAll content types

Regulatory press release12/5/2025, 7:25 AM

Boule Diagnostics Announces CEO Transition as Organization Prepares for Next Chapter

Boule Diagnostics

Regulatory press release11/21/2025, 3:00 PM

Boule Diagnostics – Nomination Committee for the Annual General Meeting 2026

Boule Diagnostics

Regulatory press release10/24/2025, 6:00 AM

Boule Diagnostics Interim Report Q3 2025

Boule Diagnostics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release10/20/2025, 8:45 AM

Boule Diagnostics – Invitation to presentation of the interim report Q3 2025

Boule Diagnostics

Regulatory press release10/13/2025, 6:35 AM

Boule Diagnostics Announces CFO Departure for New Opportunity

Boule Diagnostics

Regulatory press release7/18/2025, 6:00 AM

Boule Diagnostics Interim Report Q2 2025

Boule Diagnostics

Press release7/11/2025, 9:00 AM

Boule Diagnostics – Invitation to presentation of the interim report Q2 2025

Boule Diagnostics

Regulatory press release5/7/2025, 3:45 PM

Bulletin from the Annual General Meeting May 7, 2025 in Boule Diagnostics

Boule Diagnostics

Regulatory press release4/28/2025, 6:00 AM

Boule Diagnostics Interim Report Q1 2025

Boule Diagnostics

Press release4/23/2025, 11:00 AM

Boule Diagnostics – Invitation to presentation of the interim report Q1 2025

Boule Diagnostics

Third party research2/12/2025, 6:22 AM

Boule Diagnostics: A new round of boule(s) with lower costs - ABG

Beat on adj. EBIT but lower OCF Adj. EBIT up 8.9-9.8% for '25e-'26e Trading at 5.6x '25e EV/EBIT Higher volume but lower ASP Boule Diagnostics ended the year with sales of SEK 143.2m (+2% vs. ABGSCe 140.6m), organic growth of -1.8% (ABGSCe -4.3%), a ...

Boule Diagnostics

Third party research2/11/2025, 9:42 AM

Boule Diagnostics: Beat driven by cost savings on opex - ABG

Adj. EBIT +85% vs ABGSCe Soft cash flow generation Estimates likely up 10% on adj. EBIT Q4 results Net sales came at SEK 143.2m (+2% vs. ABGSCe 140.6m) with organic growth of -1.8% (ABGSCe -4.3%). The gross margin was 44.6% (ABGSCe 47.1%). Q4 adj. EBIT...

Boule Diagnostics

Third party research2/6/2025, 6:23 AM

Boule Diagnostics: Management efforts to improve gross margin - ABG

Q4'24 results due 11 February '25e-'26e adj. EBIT revised by 0.5-0.7% Share trading at '25e EV/EBIT of 6.3x Q4'24 expectations We expect Boule Diagnostics to deliver organic sales growth of -4% to SEK 141m in Q4'24e. Consumables performed well in Q3,...

Boule Diagnostics

Third party research10/28/2024, 6:58 AM

Boule Diagnostics: Improving gross margin but lower sales - ABG

- Adj. EBIT better but OCF down in Q3 - Transition in progress - Adj. EBIT up 7% in '24e, down 1% in '25e-'26e Mixed Q3 Boule Diagnostics reported a mixed set of numbers in Q3 with weaker-than-expected sales (-4% vs ABGSCe) but a higher gross margin ...

Boule Diagnostics

Third party research10/25/2024, 10:13 AM

Boule Diagnostics: Mixed Q3 - ABG

- Weak on sales but higher gross margin - More restrucrings to come - Estimates likely up 5-10% on adj. EBIT Q3 results Net sales came at SEK 130.4m (-4% vs. ABGSCe 136.3m) with organic growth of -2% (ABGSCe -1.0%). The gross margin was 46.8% (ABGSCe...

Boule Diagnostics

Third party research10/15/2024, 5:27 AM

Boule Diagnostics: Low sales but margin improvements in Q3e - ABG

Q3'24 results due 25 October '24e-'26e adj. EBIT revised down 0.7%-1.3% We forecast -1% organic growth and 7.7% adj. EBIT margin Q3'24 expectations We expect Boule Diagnostics to report organic sales growth of -1% in Q3'24 and adj. EBIT of SEK 10.5m ...

Boule Diagnostics

Third party research7/23/2024, 6:20 AM

Boule Diagnostics: Weak instrument sales in Q2 - ABG

- Weak Q2, -6% on sales and -25% on adj. EBIT vs ABGSCe - FCF generation held back by R&D capitalisation - We cut '24e adj. EBIT by 6.7% Soft Q2 numbers Boule Diagnostics reported weaker-than-expected Q2 results, mainly due to lower sales and gross margin...

Boule Diagnostics

Third party research7/22/2024, 6:29 AM

Boule Diagnostics: Soft Q2 on lower sales and gross margin - ABG

- 25% miss on adj EBIT - Lower on sales and weaker gross margin - Estimates likely down 5-8% on adj. EBIT Q2 results Net sales came at SEK 137m (-6% vs. ABGSCe 146.4m) with organic growth of -3.6% (ABGSCe +3.3%). The gross margin was 43.1% (ABGSCe 45...

Boule Diagnostics

Third party research7/10/2024, 6:34 AM

Boule Diagnostics: Low growth but margin improvements in Q2e - ABG

- Q2'24 results due 22 July- 24e-'26e EBIT revised down 1.0-2.1%- We expect 3.3% organic growth and 9.0% EBIT margin Q2'24 expectations We expect Boule Diagnostics to report an organic sales growth of 3.3% in Q2'24 and an EBIT margin of 9.0%, up from...

Boule Diagnostics

Regulatory press release5/8/2024, 4:15 PM

Bulletin from the Annual General Meeting May 8, 2024 in Boule Diagnostics AB

Boule Diagnostics

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.